Welcome to our dedicated page for Galecto SEC filings (Ticker: GLTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Drug discovery moves quickly, but decoding the paperwork rarely does. Galecto’s breakthroughs on galectin-3 and LOXL2 generate dense SEC disclosures packed with trial data, milestone payments and collaboration terms. If you have ever asked “what does Galecto report in its 10-K?” or searched for “Galecto insider trading Form 4 transactions,” you know the challenge of extracting what matters from hundreds of pages.
Stock Titan removes that friction. Our AI engine reads every submission the moment it reaches EDGAR, delivering plain-English highlights of each “Galecto quarterly earnings report 10-Q filing” and alerting you to “Galecto Form 4 insider transactions real-time.” Need a quick brief on a surprise 8-K? Select “Galecto 8-K material events explained” and let the platform surface the key clinical or financing update in seconds. The result is “Galecto SEC filings explained simply,” giving you more time to evaluate science instead of syntax.
Because Galecto’s value hinges on clinical progress, we link risk factors in the “Galecto annual report 10-K simplified” to pipeline milestones, map 10-Q cash-burn tables to trial timelines, and flag royalty clauses hidden in exhibits. Use our tools to:
- Monitor “Galecto executive stock transactions Form 4” ahead of catalyst dates
- Run a “Galecto earnings report filing analysis” to compare R&D trends with study results
- Review the “Galecto proxy statement executive compensation” structure beside performance goals
Whether you’re “understanding Galecto SEC documents with AI” for the first time or tracking every “Galecto insider trading Form 4” alert, Stock Titan delivers real-time coverage, expert context and AI-powered clarity—so you can focus on assessing fibrosis and oncology breakthroughs, not deciphering legal prose.
Amendment No. 5 to a Schedule 13D/A discloses that Novo Holdings A/S no longer beneficially owns any shares of Galecto, Inc. common stock. The statement amends prior Schedule 13D filings and notes that, on
Novo Holdings A/S reports holding 86,579 shares of Galecto, Inc. common stock, representing approximately 6.5% of the 1,324,560 shares outstanding as of August 1, 2025. The Schedule 13D/A updates prior filings and states that Novo Holdings has sole voting and dispositive power over the shares it holds.
The filing discloses that on September 23, 2025, Novo Holdings sold 13,334 shares in open market transactions at prices between $4.00 and $4.85, with a weighted average sales price of $4.2295 per share. The statement clarifies Novo Holdings role as a Danish holding company managing assets of the Novo Nordisk Foundation and confirms no convictions or disqualifying civil judgments in the past five years for the reporting entities or listed officers.
Galecto, Inc. (GLTO) – Form 4 insider filing
On 18 June 2025, non-employee director Dallas Jayson Donald Alexander received an automatic grant of 720 stock options under the company’s Director Compensation Policy. The options carry an exercise price of $3.22 per share, a 10-year term expiring 18 June 2035, and will vest in equal monthly installments over one year. The filing lists the director’s ownership as direct and discloses no sales or other equity transactions.
Given the small size of the grant and its routine nature, the disclosure is unlikely to have a material impact on Galecto’s valuation or trading dynamics; however, it does incrementally align director incentives with shareholder value through equity-based compensation.
Galecto (NASDAQ: GLTO) submitted a routine Form 4 detailing a small insider equity grant.
On 18 June 2025, director Amit Munshi received a stock option for 720 common shares at an exercise price of $3.22 per share. The grant was issued under the company’s Non-Employee Director Compensation Policy in conjunction with the 2025 Annual Meeting. The option vests in equal monthly installments over one year and expires on 18 June 2035. Following the transaction, Munshi beneficially owns 720 derivative securities; no non-derivative share holdings were reported.
The filing is administrative in nature, disclosing routine director compensation with no material impact on Galecto’s financial position or governance profile.
Galecto (NASDAQ:GLTO) filed a routine Form 4 reporting that director David Shapiro received a stock option for 720 common shares at an exercise price of $3.22 on June 18, 2025. The award was granted under the company’s Non-Employee Director Compensation Policy and will vest in equal monthly installments until the first anniversary of the grant date. No shares were sold or otherwise disposed of, and Shapiro now directly holds 720 derivative securities following the reported transaction.
FAQ
What is the current stock price of Galecto (GLTO)?
What is the market cap of Galecto (GLTO)?
